THE ROLE OF ANTIBIOTICS, RIFAXIMIN VERSUS CIPROFLOXACIN IN INDUCTION OF REMISSION IN ULCERATIVE COLITIS
2021
Patients with ulcerative colitis (UC) get a variety of treatments, including antibiotics. The purpose of this metaanalysis
of randomised controlled trials was to determine whether antibiotic medication improves the clinical
symptoms of inflammatory bowel disease. A search of the Medline and Scopus databases was conducted, as well as
a systematic review. Randomized controlled trials comparing rifaximin therapy to ciprofloxacin therapy were
conducted. The study enrolled a total of 60 patients with ulcerative colitis. The period between the start and end of
the treatment of the last unformed stool among the two categories of ulcerative colitis patients taking rifaximin or
ciprofloxacin was evaluated. There was no considerate dissimilarity in two groups in regards to clinical
improvement during the initial 24 hours (P =.199), failed to treat ulcerative colitis (P =.411), or microbiological fix
(P =.222). Adverse events happened at a moderate and steady rate in each group. In the treatment of ulcerative
colitis, rifaximin is a protected and compelling option in contrast to ciprofloxacin.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI